What we know about the higher prevalence of thrombi in young women vaccinated with AstraZeneca and Janssen

If the preliminary data seem to point, very slightly, to a higher prevalence of thrombi in women in general, and young women in particular, who have received the AstraZeneca vaccine, should we advise against getting this group of people vaccinated? Is it the same with other medications? Are women simply more prone to thrombi?

We are going to try to answer all these questions, while contextualizing the risks we face.

Read more